Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

malignant

malignant is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 118
News articles 0
Drug details — malignant
Class
—
Route
—
Patents
20
Programs
118
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

malignant is an FDA-listed pharmaceutical active ingredient.

Key facts

INN malignant

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 68Ga-PSMA-11 Phase 3 · Chinese Academy of · Biochemical Recurrence of Malignant Neoplasm of Prostate
  2. Bupivacaine Phase 3 · Pacira Ireland · Malignant Neoplasms of Female Genital Organs
  3. CO-338-087 Phase 3 · pharma& · Ovarian epithelial cancer, Malignant peritoneal neoplasm, ad
  4. Dabrafenib Phase 3 · Novartis India · Malignant Melanoma
  5. Darleukin, Fibromun Phase 3 · Philogen · Malignant melanoma of the skin in patients with locally adva
  6. Futibatinib, FULVESTRANT Phase 3 · Taiho Pharma Canada · Malignant Solid Tumors
  7. MO29406 Phase 3 · HOFFMANN-LA ROCHE · Solid Malignant Tumors
  8. Palliative Chemotherapy Phase 3 · Sun Yat-sen University · Colorectal Neoplasms Malignant

Related patents

Browse patents

  1. US 11980607

    Methods of treating malignant lymphoproliferative disorders

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11885806

    Method for depleting malignant T-cells

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11885807

    Method for depleting malignant T-cells

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11510904

    Methods of treating malignant lymphoproliferative disorders

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11385233

    Methods of depleting malignant T-cells

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10568901

    Micro-RNA for the treatment of malignant solid tumors and metastasis

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10172937

    Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9808505

    Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9242000

    Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8951971

    Lymphatic zip codes in tumors and pre-malignant lesions

    Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8598316

    Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8536132

    Lymphatic zip codes in tumors and pre-malignant lesions

    Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7919466

    Lymphatic zip codes in tumors and pre-malignant lesions

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7855191

    Agent having a destructive effect on malignant tumors and method for the production thereof

    Expires Mon Dec 16 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7723474

    Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies

    Expires Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7598341

    Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs

    Expires Mon Oct 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7354582

    Use of VEGF antagonists for the treatment of malignant gliomas

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7118752

    Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I

    Expires Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 6720344

    Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants

    Expires Mon Apr 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  20. US 6299873

    Method for improvement of radiation therapy of malignant tumors

    Expires Mon Oct 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is malignant?

malignant is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.